Viral specific VST Infusion

BIOLOGICAL2 trials

Sponsors

Children's Hospital Medical Center, Cincinnati

Conditions

Allogeneic Stem Cell TransplantInfection in an Immunocompromised HostViral InfectionViral Reactivation

Phase 1

Donor-Derived Viral Specific T-cells (VSTs)

RecruitingNCT02048332

Children's Hospital Medical Center, CincinnatiAllogeneic Stem Cell Transplant, Viral Infection, Viral Reactivation

Start: 2014-02-05End: 2027-01-01Target: 1000Updated: 2026-09-04

Phase 2

Third Party Viral Specific T-cells (VSTs)

RecruitingNCT02532452

Children's Hospital Medical Center, CincinnatiInfection in an Immunocompromised Host, Viral Infection, Viral Reactivation

Start: 2015-09-02End: 2029-12-01Target: 1000Updated: 2026-09-04

Related Papers

Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction.

2025-12-01

Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults

Transplantation and Cellular Therapy2023-02-0323 citations

Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant

Blood Advances2022-02-0226 citations

Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted

Blood Advances2021-09-0253 citations

Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients.

PubMed2020-11-2475 citations